Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ritlecitinib higher dose

Phase 3

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Severe Alopecia AreataActive, not recruiting

Severe Alopecia AreataPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Severe Alopecia Areata

NCT07029711

Clinical

Trials by Indication[1]

Severe Alopecia Areata1 trial

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT07029711·208 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ritlecitinib higher dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ritlecitinib higher dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Pfizer

Related News